The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

An early study with chimeric receptors between the alpha2c-adrenergic receptor and m3-muscarinic receptor suggested ... occur during dimerization. Two mechanisms have been proposed for GPCR ...

At present no definitive medical treatment exists for acute pancreatitis. [9,10] Pirenzepine has shown encouraging positive responses and a low incidence of adverse effects when used to treat ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

The M1/M4 muscarinic receptor agonist is vying to be the first drug to reach the market for schizophrenia with a new mechanism of action in decades. It is also in phase 3 clinical testing as an ...